X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): OPC1
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: OPC1
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Lineagen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 08, 2021
Details:
Lineage and Neurgain will collaborate on the clinical testing of Neurgain’s novel Parenchymal Delivery Injection system, OPC1 , which is designed to allow for the administration of cells to the spinal cord without stopping the patient’s respiration.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): OPC1
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: OPC1
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2020
Details:
A new ready-to-inject formulation of OPC1, which enables clinical use at a much larger number of spinal cord treatment centers, accelerating enrollment for a larger and potentially registrational clinical trial.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AIV001
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: AIV001
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2020
Details:
AIV001 was shown to be safe and well tolerated after local intradermal treatment of incisional wounds. Reduction in fibrosis was observed from single AIV001 treatment post-wounding.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): OPC1
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: OPC1
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2020
Details:
Lineage has strengthened its patent position in order to protect the OPC1 processes, product and composition, and methods of use. Multiple OPC1 batches have been successfully manufactured; GMP production is planned to begin in early 2021.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
